PerCP anti-mouse CD3ε Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Armenian Hamster

Immunogen

H-2K^b-specific mouse cytotoxic T lymphocyte clone BM10-37

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.

Excitation Laser

Blue Laser (488 nm)

Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis¹, as well as T cell activation assays, inducing proliferation and cytokine production^1,2,7,12,16. It also induces apoptosis in immature thymocytes³²,  and in vivo T cell depletion^8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation¹, immunohistochemical staining^14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting⁴, complement-mediated cytotoxicity⁶, in vitro and in vivo stimulation of T cells^1,2,7,12,16, immunofluorescent staining⁵, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells¹¹. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)

Product Citations

1. Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed
2. Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed
3. Ajay AK, et al. 2022. Cell Rep. 38:110473. PubMed
4. Könnecke I, et al. 2014. Bone. 64c:155. PubMed
5. Cabrera-Mora M, et al. 2016. J Immunol. 197: 2748 - 2761. PubMed
6. Li P, et al. 2020. J Cell Mol Med. 24:10151. PubMed
7. Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed
8. Xu X, et al. 2020. Chin Med. 15:33. PubMed
9. Li X, et al. 2023. J Clin Invest. 133:. PubMed
10. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
11. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
12. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
13. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
14. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
15. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
16. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
17. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
18. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
19. Neumann AM et al. 2017. PloS one. 12(11):e0187330 . PubMed
20. Xie X, et al. 2010. Proc Natl Acad Sci U S A. 107:8754. PubMed
21. Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
22. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
23. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
24. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
25. Ma YS, et al. 2021. Mol Ther Oncolytics. 484:20. PubMed
26. Cha H, et al. 2010. J Immunol. 184:6799. PubMed
27. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
28. Pérez-Girón J, et al. 2015. J Vis Exp. 100: 52803. PubMed
29. Chang J, et al. 2010. PLoS One. 5:e12925. PubMed
30. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
31. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
32. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
33. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
34. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
35. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
36. Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed
37. Terp MG, et al. 2021. Mol Oncol. 15:3299. PubMed
38. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
39. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
40. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
41. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
42. Stack G, et al. 2015. PLoS Pathog. 11:1004641. PubMed
43. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
44. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed

RRID

AB_893317 (BioLegend Cat. No. 100325)
AB_893317 (BioLegend Cat. No. 100326)

Antigen Details

Structure

Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD

Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function

TCR signal transduction, T cell activation, antigen recognition

Ligand/Receptor

Peptide antigen/MHC-complex

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, TCRs

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID

12501 View all products for this Gene ID

UniProt

View information about CD3epsilon on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats